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Abstract
Structures of the multidrug-binding repressor protein QacR with monovalent and bivalent cationic drugs revealed that the
carboxylate side-chains of E90 and E120 were proximal to the positively charged nitrogens of the ligands ethidium,
malachite green and rhodamine 6G, and therefore may contribute to drug neutralization and binding affinity. Here, we
report structural, biochemical and in vivo effects of substituting these glutamate residues. Unexpectedly, substitutions had
little impact on ligand affinity or in vivo induction capabilities. Structures of QacR(E90Q) and QacR(E120Q) with ethidium or
malachite green took similar global conformations that differed significantly from all previously described QacR-drug
complexes but still prohibited binding to cognate DNA. Strikingly, the QacR(E90Q)-rhodamine 6G complex revealed two
mutually exclusive rhodamine 6G binding sites. Despite multiple structural changes, all drug binding was essentially
isoenergetic. Thus, these data strongly suggest that rather than contributing significantly to ligand binding affinity, the role
of acidic residues lining the QacR multidrug-binding pocket is primarily to attract and guide cationic drugs to the ‘‘best
available’’ positions within the pocket that elicit QacR induction.
Citation: Peters KM, Brooks BE, Schumacher MA, Skurray RA, Brennan RG, et al. (2011) A Single Acidic Residue Can Guide Binding Site Selection but Does Not
Govern QacR Cationic-Drug Affinity. PLoS ONE 6(1): e15974. doi:10.1371/journal.pone.0015974
Editor: Hendrik W. van Veen, University of Cambridge, United Kingdom
Received September 16, 2010; Accepted December 7, 2010; Published January 17, 2011
Copyright:  2011 Peters et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Project Grant 301941 from the National Health and Medical Research Council (Australia) (to R.A.S. and M.H.B.) and by grant
AI048593 from the National Institutes of Health Grant (to R.G.B.). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: melissa.brown@flinders.edu.au (MHB); rgbrenna@mdanderson.org (RGB)
. These authors contributed equally to this work.
¤ Current address: Department of Biochemistry, Duke University, Durham, North Carolina, United States of America
Introduction
The emergence of multidrug resistant pathogens is an ongoing
global clinical concern and is significantly driven by the action of
multidrug efflux transporters [1,2]. Capable of exporting a diverse
array of structurally and chemically dissimilar drugs from the cell,
deciphering the structural mechanisms that govern the polyspecific
substrate recognition of these proteins will likely be crucial for the
development of future chemotherapeutics.
The detailed structural analyses of the Staphylococcus aureus
multidrug-binding repressor QacR, bound to multiple cationic
lipophilic compounds and to two compounds simultaneously [3–
5], have been influential in affording early insight into the basic
principles that govern protein-multidrug interactions. A member
of the TetR family of transcriptional regulators [6–8], QacR is a
dimer composed of nine alpha helices in which helices a1-3
comprise the helix-turn-helix (HTH) containing DNA-binding
domain connected via helix a4 to helices a5-a9, which form the
dimerization and multidrug-binding domain (Figure 1A).
QacR represses transcription of the qacA multidrug efflux
transporter gene by binding as a pair of dimers to the IR1 DNA
operator sequence, a large inverted repeat that overlaps the qacA
promoter (PqacA) [9,10]. Drug binding occurs with a stoichiometry
of one drug per QacR dimer and elicits a coil-to-helix transition of
residues T89 through Y93 in the ligand-bound subunit resulting in
the expulsion of Y92 and Y93 from the interior of the protein and
the formation of the multidrug-binding pocket [3]. This key
conformational change also instigates the relocation of the DNA-
binding domain, with concomitant smaller changes in the ligand-
free subunit resulting in a QacR structure no longer able to bind to
the IR1 operator site [3], thus allowing up-regulation of qacA
transcription.
The QacR multidrug-binding pocket contains two distinct but
partially overlapping binding sites designated the rhodamine 6G
(R6G) and ethidium (Et) sites after their respectively bound drugs.
Key components of this multidrug-binding pocket are five
glutamates (Figure 1A), multiple aromatics and several polar and
nonpolar residues [3]. Notably, although each cationic drug
contacts a distinct subset of QacR residues, all, with the exception
of pentamidine (Pt), which is complemented by E63, p-p, cation-p
and dipole-charge interactions [5], interact with one or more of
the four glutamate residues (E57, E58, E90 and E120) that have
been proposed to neutralize their positive charge [3–5]. Specifi-
cally, E90 interacts with R6G and malachite green (MG) whilst
E120 interacts with Et, MG and one of the two positively-charged
aminomethylquinolinium moieties of the bivalent drug dequali-
nium (Dq) [3]. Indeed, many multidrug-binding proteins includ-
ing; the Bacillus subtilis BmrR transcriptional activator [11,12], the
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transport proteins MdfA and EmrE in Escherichia coli [15,16],
QacA in S. aureus [17,18] and LmrP in Lactococcus lactis [19],
predominantly bind cationic substrates with negatively-charged
residues featuring prominently in the recognition process. A
similar, but inverse importance is found for the regulator TtgR
from Pseudomonas putida and CmeR from Campylobacter jejuni, TetR
family members that utilize arginine, lysine or histidine residues
for high affinity ligand binding to their anionic inducing
compounds [14,20].
In order to delineate the precise role of the acidic residues
within the QacR multidrug-binding pocket in ligand binding and
induction, each should be substituted with uncharged side chains,
e.g., by alanine or isosterically by glutamine and biochemically
and structurally characterized. Surprisingly, such substitutions of
residues E57 and E58 caused little change in the binding location
or affinity of several drugs with one exception [21]. That exception
was the binding of berberine (Be) to QacR(E58Q), whereby the
structure revealed a ,180u rotation of the drug such that new
charge neutralization contacts are made to the hydroxyl group of
T89 with perhaps some contribution from E90. Intriguingly, this
new binding mode increased the affinity of QacR(E58Q) for Be by
four-fold. The effects of the removal of the formal negative charges
from QacR residues E90 and E120 are unknown. Hence,
QacR(E90Q), QacR(E90A), QacR(E120Q), and QacR(E120A)
proteins were constructed, purified and tested for their ability to
bind to the ligands R6G, MG, Et and Dq. The mutated proteins
were analyzed for their ability to bind these drugs both in vitro and
in vivo, and the structures of QacR(E90Q) and QacR(E120Q) in
complex with them was determined. The data reveal a striking
finding. Similar to residues E57 and E58, glutamine residues at
positions 90 and 120 contribute little to cationic multidrug-binding
affinity. Rather, in combination with E57, E58 and E63, residues
E90 and E120 appear to be responsible for determining the
preferred binding location of each individual drug in the
multifaceted multidrug-binding pocket and may be utilized to
preclude anionic and neutral compounds via their collective
negative electrostatic field.
Results and Discussion
Drug-binding affinities of the QacR mutants in vitro
Drug-binding affinities of wild type (wt), E90 and E120 mutant
QacR proteins were determined for MG, R6G and Et utilizing
fluorescence quenching of intrinsic tryptophan residues or
isothermal titration calorimetry (ITC) for Dq since it displayed
significant fluorescence at 340 nm (Figures S1–S5). Unexpectedly,
the QacR E90 and E120 mutants displayed only modest effects, no
greater than 2.7-fold, on the affinities for the drugs examined
(Table 1) indicating clearly that these charged residues are
relatively minor contributors to drug-binding affinity.
Induction capabilities of the QacR mutants in S. aureus
b-lactamase reporter gene assays were used to determine the
ability of the QacR mutant proteins to dissociate from IR1
operator DNA in the presence of the inducing compounds Et, Dq,
MG and R6G in S. aureus. To ensure that NorA, a chromosomally-
encoded multidrug resistance transporter that shares a number of
substrates with QacA [18,22,23] did not mask the ability of
Figure 1. The conformational plasticity of QacR. A) Structure of the wild type QacR-malachite green (MG) complex (space group P42212). QacR
is shown as a light blue ribbon. The nine a helices, N- and C-termini, and DNA- and drug-binding domains are labelled. MG is shown as light blue
sticks and the acidic residues of the multidrug-binding pocket, residues E57, E58, E63, E90, and E120, are shown as red sticks. B and C)
Superimpositions of one subunit of wild type QacR bound to IR1 DNA (space group P65, magenta ribbon) and MG (space group P42212, blue ribbon),
and QacR(E90Q) bound to MG (space group P62, yellow ribbon) highlighting the pendulum motion of helix a4 (B) and the bending and rotation of
helix a7 originating at residue A126 (C) that lead to reorientation of the recognition helices (Hr) of the DNA-binding domain.
doi:10.1371/journal.pone.0015974.g001
Table 1. Effect of substitutions of QacR residues E90 and







wt 2.3560.13 0.9060.50 1.2360.14 0.3960.02
E90A 1.0360.09 1.8060.07 1.4960.10 0.2160.02
E90Q 1.1860.04 2.2060.60 1.7460.02 0.4860.05
E120A 1.2560.15 2.4060.60 0.9860.32 0.1760.01
E120Q 1.1660.09 2.3060.50 1.3960.14 0.5860.04
aValues represent an average of three separate experiments. Drug binding was
measured by tryptophan fluorescence for Et, MG and R6G and by isothermal
titration calorimetry for Dq.
doi:10.1371/journal.pone.0015974.t001
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strain RN4220 norA::erm (SAK1759) [24] was employed. The blaZ
reporter gene vector pSK5645 [25], and derivatives encoding the
wt and mutant QacR proteins, were electroporated into this strain
and immunological detection was used to determine mutant
protein stability relative to wt QacR protein. The QacR E90 and
E120 mutant proteins were present at wt levels (data not shown).
Background b-lactamase activity detected from S. aureus
SAK1759 strain harboring the pSK5645 plasmid was minimal
and was used for normalization. With the exception of QacR
E90A, which displayed double the basal induction level, the basal
level of expression from PqacA for the QacR mutants was the same
as for wt (Table 2), indicating that DNA-binding was not impaired
by these mutations in the QacR multidrug-binding pocket.
Inducing compounds were used at concentrations that were below
minimum inhibitory concentrations for S. aureus containing the
large multidrug resistance plasmid pSK1 (data not shown), the
natural resource of the qacA-R locus, and that afforded maximal
induction from PqacA in the presence of wt QacR. All compounds
induced a 2.0- to 3.6-fold increase from the basal level of
expression from PqacA in the presence of wt QacR (Table 2). QacR
mutants were also induced in the presence of the drugs examined
and displayed similar maximal induction values to those seen with
wt QacR in S. aureus (Table 2), commensurate with their essentially
wt drug-binding affinities in vitro (Table 1).
Overall structure of the QacR mutant-drug complexes
To understand the lack of significant change in the QacR drug-
binding affinities and induction capabilities following substitution
of residues E90 and E120, the glutamine-substituted QacR(E90Q)
and QacR(E120Q) proteins were crystallized in complex with
four structurally dissimilar ligands. Structures of QacR(E90Q)
and QacR(E120Q) bound to Et, Dq, MG and R6G were
solved to 2.8 A ˚, 3.3 A ˚, 2.2 A ˚ and 2.9 A ˚ resolution, or 3.3 A ˚,
2.9 A ˚, 2.4 A ˚ and 3.2 A ˚ resolution respectively (Table S1 and
Figures S6–S7). The atomic coordinates and structure, factors for
the QacR(E90Q)-Dq, QacR(E90Q)-Et, QacR(E90Q)-MG, Qa-
cR(E90Q)-R6G, QacR(E120Q)-Dq, QacR(E120Q)-MG and Qa-
cR(E120Q)-R6G complexes have been deposited in the Protein
Data Bank (http://www.pdb.org) under the accession codes 3br1,
3pm1, 3bqz, 3br5, 3br2, 3br0 and 3br6, respectively. With the
exception of Et in complex with QacR(E120Q), wherein no drug
density could be clearly ascribed and hence is not discussed
further, electron density for each drug was clear and, as observed
in previous wt QacR-drug complexes [3,5], these mutants bound
to each drug in a one drug per QacR dimer stoichiometry (data
not shown). Structures of QacR(E90Q) and QacR(E120Q) in
complex with R6G and Dq crystallized in the same tetragonal
P42212 space group as did all of the previously described QacR-
drug complexes [3,5]. Comparison of each of these mutant
complexes with the corresponding wt QacR-drug complex gave
root mean square deviations (RMSD) of 0.7 A ˚ for all correspond-
ing Ca atoms, indicating no significant global structural changes.
By contrast, QacR(E90Q) and QacR(E120Q) in complex with Et
and MG crystallized in the hexagonal space group P62 (Table S1).
A new drug-induced conformation of QacR
Structural comparison of the hexagonal QacR mutant-drug
complexes with the corresponding tetragonal wt QacR-drug
complex revealed a new QacR conformation (with global RMSDs
of ,2.0 A ˚ between all corresponding Ca atoms) in which notably,
residues 89 through 93 had undergone the coil-to-helix transition,
the structural hallmark of drug-mediated induction. Comparably
few structural differences are noticeable between the individually
superimposed DNA-binding domains (RMSDs #0.8 A ˚), contain-
ing the HTH region, or multidrug-binding domains (RMSDs
#1.3 A ˚) of each QacR subunit, with the most prominent
conformational changes apparent in helices a4 and a7 of the
multidrug-binding domains which lend to flexibility in the inter-
domain orientations.
Superimposition of helices a8 and a9 and their two-fold mates,
which together form the dimerization interface and do not move
in response to either DNA or drug binding, indicated that the
distal ends of helices a4 and a7 of each hexagonal conformer were
tilted and rotated in a counter-clockwise direction (CCD) relative
to the tetragonal form (Figures 1B–C). Helix a4 moved as a rigid
body in a pendulum motion whereas a7 is bent and rotated
around residue A126 (Figure 1C). As a direct consequence of its
attachment to a4, the DNA-binding domain is rotated in the same
CCD by ,5u from the tetragonal conformer, placing it ,31u
clockwise relative to DNA-bound QacR (Figure 1B). A similar
degree of twisting was transmitted in both subunits of the
hexagonal dimer. Thus, the hexagonal form of QacR exhibits a
closer approach of the DNA-binding domains, and therefore the
recognition helices, with their centre-to-centre distance now
39.1 A ˚ compared with 46.4 A ˚ for the tetragonal conformer. This
diminished distance is similar to that found between the
recognition helices of the DNA-bound form of QacR [3,10].
Table 2. Effect of substitutions of QacR residues E90 and E120 on induction in vivo.
Compound (mM)

























wt 0.0760.01 0.1460.00 2.0 0.2260.02 3.1 0.1760.03 2.4 0.2460.01 3.6
E90A 0.1460.01 0.1960.02 1.4 0.2360.00 1.6 0.1760.00 1.2 0.2460.02 1.7
E90Q 0.0860.01 0.1360.00 1.6 0.2260.01 2.8 0.2060.00 2.5 0.2060.03 2.5
E120A 0.0560.01 0.1060.02 2.0 0.2260.01 4.4 0.1260.01 2.4 0.2160.01 4.2
E120Q 0.0760.00 0.1060.00 1.4 0.2160.01 2.6 0.1260.03 1.7 0.1960.00 2.4
aValues, derived from the average of at least two b-lactamase reporter gene assays, are expressed in units, where 1 unit is equivalent to 1 mM of nitrocefin hydrolyzed/
min at 37uC. Basal induction was measured in the absence of inducing drug and the concentrations of the QacR ligands required for maximal induction of wt QacR are
17.09 mM Et, 1.90 mM Dq, 1.25 mM MG, and 0.95 mM R6G, respectively.
doi:10.1371/journal.pone.0015974.t002
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MG onto those of the DNA-bound QacR reveals multiple steric
clashes between the hexagonal conformation and the IR1 operator
binding site whereby L3 of helix a1 of one subunit is 1.5 A ˚ from
the phosphate backbone, the side chain of T24 of helix a2 is 0.7 A ˚
from the phosphate backbone, and the N-termini of the
recognition helices clash with DNA bases, e.g., K36 is 2.1 A ˚ and
2.7 A ˚ from the O4 and C7 of one of the thymidines within IR1
(Figure S8). Therefore, the less open but twisted hexagonal QacR
conformer is a new, perhaps minimally-induced structure with the
more open tetragonal form delimiting the conformational
plasticity of drug-bound QacR. Such conformational flexibility
also has been observed in the drug-bound form of other TetR
family members. Crystal structures of drug-bound EthR and
ligand-bound CprB indicated conformational flexibility that allows
5A ˚ and 2 A ˚ fluctuations, respectively, in the center-to-center
distances of the recognition helices of each repressor protein
[26,27]. Such conformational plasticity is also observed for TetR
family member AcrR in the absence of multidrug binding,
whereby two drug-free structures showed that the recognition
helices can flex by at least 3 A ˚ [13,28,29].
QacR mutant-drug interactions: QacR(E90)-Dq and
QacR(E120Q)-Dq
The drug-binding site occupied by Dq in the QacR(E90Q)-Dq
and QacR(E120Q)-Dq complex structures is nearly identical
to that which it takes in the wt QacR-Dq structure and also
maintains the majority of protein-drug contacts (Figures 2A and
3A and Table S2). Specifically, Dq spans the length of the
multidrug-binding pocket such that one aminomethylquinolinium
group remains sandwiched between the aromatic side chains of
residues W61 and Y93 in the R6G sub-pocket, and the other
between F1629 (where prime indicates the second subunit of the
dimer) and Y103 in the Et sub-pocket. Since E90 does not contact
Figure 2. Multidrug binding by QacR(E90Q). A - E) Superimpositions of the structures of the multidrug-binding pockets of wild type (wt) QacR-
drug (light blue) and the corresponding QacR(E90Q)-drug (yellow) complexes. For clarity, only the side chains of QacR residues that are within 5 A ˚ of
(A) dequalinium (Dq), (B) ethidium (Et), (C) malachite green (MG), (D) rhodamine 6G (R6G) site 1, and (E) rhodamine 6G (R6G) site 2, are shown and
labelled. Helices containing drug-interacting residues are labelled in black, and carbon, nitrogen and oxygen atoms are coloured light blue or yellow,
blue and red, respectively. The salt bridge between QacR residues E90 and H164 in the wt QacR-Dq and wt-QacR R6G structures is shown as a dashed
line in panels A and E. The imidazoles that are found in the drug-binding pocket of the QacR(E90Q)-MG complex are shown and labelled.
doi:10.1371/journal.pone.0015974.g002
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binding site in the structure of QacR(E90Q)-Dq was not
unexpected. Nevertheless, although one of the two positively
charged moieties of Dq remained complemented by the
carboxylate of residue E120, the E90Q substitution resulted in
the loss of a salt bridge between the side chains of H164 and E90.
This now untethered glutamine side chain swings to within 3.6 A ˚
of Dq, resulting in the twisting of the proximal aminomethylqui-
nolinium head group by 25u from its wt orientation (Figure 2A). In
doing so, there is a 1.5 A ˚ increase in distance between the
positively charged N2 nitrogen atom of this Dq moiety and the
side chain carboxylate of the ‘‘charge-neutralizing’’ residue E57
(4.8 A ˚ in the wt QacR-Dq complex to 6.2 A ˚ in the QacR(E90Q)-
Dq complex). However, alternative, and essentially isoenergetic
charge complementation is provided by E58 located 6.1 A ˚ from
N2 in the wt QacR-Dq complex and 4.8 A ˚ in the QacR(E90Q)-
Dq complex. Consequently, the QacR E90Q substitution is
associated with only a moderate and unsurprising 2.4-fold
decrease in Dq binding affinity and no impact on induction as
observed in the presence of this drug in S. aureus (Tables 1 and 2).
Indeed, such swapping is analogous to that observed for the
mutant proteins QacR(E57Q) and QacR(E58Q) in complex with
Dq, wherein residues E57 and E58 afforded immediate functional
and chemical redundancy following substitution of either side
chain with alanine or glutamine [21].
As observed for QacR(E90Q), the QacR(E120Q) protein
retains a near wt level binding affinity for Dq and Dq-induction
capability in S. aureus (Tables 1 and 2). This retention occurs
despite the loss of the ‘‘direct’’ charge complementation of one of
the positively charged aminomethylquinolinium groups by the
carboxylate of E120 (Figure 3A and Table S2). Intriguingly, no
acidic residue is within 6 A ˚ of this positively charged moiety in the
QacR(E120Q)-Dq structure. However, the essentially wt in vitro
and in vivo properties of this mutant can be attributed in great part
to the retention of the majority of QacR-Dq contacts, including a
stronger E57-aminomethylquinolinium interaction, as well as the
alternative ‘‘neutralization’’ of the other aminomethylquinolinium
moiety by cation-p interactions with the aromatic side chains of
Y103 and F1629 and the dipole-charge interaction between the
glutamine Oe atom and N1 (Table S2).
QacR(E90Q)-MG, QacR(E120Q)-MG and QacR(E120Q)-R6G
An essentially wt binding mode is observed for MG in the
QacR(E90Q)-MG and QacR(E120Q)-MG structures (Figures 2C
and 3B and Table S2). Importantly, the charge of this monovalent
cationic drug remained complemented by the unsubstituted
carboxylate of either E90 or E120, with the alanine or glutamine
substitution of either residue having little impact on binding
affinity or induction capabilities of MG (Tables 1 and 2).
Analogous to the finding that residues E57 and E58 can
functionally substitute for one another in binding Dq [21],
residues E90 and E120 appear to provide functional redundancy
for MG binding. As expected, the binding site occupied by R6G in
the QacR(E120Q)-R6G structure was identical to that in the wt
QacR-R6G structure, with the same protein-drug interactions
including the charge complementation of this cation by E90
(Figure 3C and Table S2).
Collectively, these data indicate that, in direct contrast to the
multidrug-binding proteins EmrE, QacA, LmrP, AcrR and BmrR,
for which acidic residues have been shown to provide a direct and
significant energetic contribution to ligand binding [11,12,14–19],
residues E90 and E120 are not critical for QacR-cation
neutralization or binding affinity. Interestingly, mutational studies
with the E. coli multidrug exporter MdfA also revealed that
although negatively-charged amino acids play a role in substrate
recognition and transport their electrostatic interaction is not
mandatory for the binding process with cationic substrates [30,31].
The significant loss of QacR multidrug-binding ability following
the seemingly unfavourable mutations of acidic residues is
apparently circumvented primarily by new stacking, van der
Waals and dipole-drug interactions between different sets of
proximal aromatic and polar residues, underscoring the chemical
redundancy of the QacR multidrug-binding pocket [3,21]. Indeed,
partial charge complementation of Dq by non-acidic residues in
Figure 3. Multidrug binding by QacR(E120Q). Superimpositions of the structures of the multidrug-binding pockets of wild type QacR-drug
(light blue) and the corresponding QacR(E120Q)-drug (orange) complexes. For clarity, only the side chains of QacR residues that are within 5 A ˚ of (A)
dequalinium (Dq), (B) malachite green (MG), and (C) rhodamine 6G (R6G), are shown. Helices containing drug-interacting residues are labelled in
black, and carbon, nitrogen and oxygen atoms are coloured light blue or orange, blue and red, respectively.
doi:10.1371/journal.pone.0015974.g003
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observations regarding the neutralization of the bivalent drug Pt
by wt QacR [5]. Although in the QacR-Pt complex Pt bound
uniquely, by bending into the core of the protein rather than
spanning the multidrug-binding pocket like Dq, one of its
positively charged benzamidine moieties was neutralized by the
carboxylate of E63 and the other, not by acidic residues, but by
side chain and carbonyl oxygen atoms contributed by residues
S86, Y127, A153 and N157 [5].
One notable new feature of the QacR-MG interaction was
revealed by the higher resolution of the QacR(E90Q)-MG and
QacR(E120Q)-MG structures (Figures 2B and 3B, and Figures
S6C and S7B). Imidazole was observed as two disks of electron
density in a pocket between MG and the residues E120 and Y123.
The discovery of imidazole in the binding pocket is not surprising
as imidazole, which is used in QacR affinity purification and aids
in its solubility, is an aromatic cation mimic and thus similar to
most of the known QacR ligands. Indeed, four imidazoles were
identified in the multidrug-binding pocket of BmrR [12]. The
imidazoles bind a site similar to that of the decane linker of Dq in
the wt-QacR-Dq, QacR(E90Q)-Dq and QacR(E120Q)-Dq struc-
tures (Figures 2A and C and 3A–B).
QacR(E90Q)-Et and QacR(E90Q)R6G
Additional intriguing dimensions to the recognized promiscuity
of QacR-multidrug interactions are highlighted by the significantly
altered binding position of Et in the QacR(E90Q)-Et complex
and the two distinct R6G binding sites found in the structure of
QacR(E90Q)-R6G. Although charge neutralization of Et was
ascribed solely to E120 in the wt QacR-drug complex [3], the
location of Et in the QacR(E90Q)-Et structure is dramatically
altered (Figures 2B and 4). Indeed, 2Fo-Fc composite omit maps
revealed strong and full electron density for Et in this newly
revealed binding site despite having relatively high average B-
factors (Figure S6B, Table S1). In this QacR(E90Q)-Et complex,
Et is angled at 120u relative to its wt orientation and shifted toward
the R6G sub-pocket, hence overlapping the Et and R6G sub-
pockets and taking a position that is comparable to that occupied
by MG (Figure 4). From this location Et now interacts with a new
complement of residues distinct from that observed in the wt
QacR-Et complex, with a number of drug contacts gained and
lost. Lost are van der Waals contacts with the side chains of I99
and I100 and aromatic stacking interactions with F1629 and Y103,
the latter residue shifting from a position that would have clashed
with Et in the QacR(E90Q)-Et structure. Nevertheless, Et gains
stacking interactions with W61 and van der Waals contacts with
S86, M116 and N154. Further, the drug maintains contacts with
the side chains of residues Q96, E120, Y123 and N157, although
the nature of these interactions, in some instances, is altered
dramatically. Indeed, in the QacR(E90Q)-Et structure, the side
chain of E120, despite remaining within 4 A ˚ of the Et
phenanthridinium ring system, is repositioned to avoid a clash
with the drug, shifting by 3.0 A ˚ so that it is no longer available to
charge complement the Et N5 nitrogen atom (E120-N5 distance
=4.0 A ˚ in the wt QacR-Et complex and 7.0 A ˚ in the
QacR(E90Q)-Et complex). This lost interaction is replaced by a
cation-p interaction with Y123 which now stacks with Et.
Additionally, the side chain of E90Q swings further into the
binding pocket to a position comparable to that observed in the
QacR(E90Q)-Dq structure (Figures 2A–B). Thus, relocation of Et
in the binding pocket of QacR(E90Q)-Et is apparently, although
somewhat enigmatically, driven by the QacR mutation E90Q and
subsequent reorientation of the side chains of E90Q, Y103 and
E120. Despite the loss of interaction with E90 and employing an
almost entirely new complement of QacR residues, this new
binding site in the QacR(E90Q)-Et complex exhibited binding
affinity and induction capabilities for Et essentially the same as wt
QacR (Tables 1 and 2).
In the wt QacR-R6G complex, R6G binds towards the ‘‘top’’ of
the multidrug-binding pocket and is complemented electrostati-
cally by E90 [3]. Strikingly, when bound to QacR(E90Q), R6G
can now occupy two binding sites (Figures 2D–E). In one site the
drug is oriented as observed in the wt QacR-R6G complex
(Figure 2D), whereas in the second site the drug is located similarly
to Et in the QacR(E90Q)-Et complex, such that R6G (and Et) are
bound in a manner comparable to MG, i.e., R6G and Et converge
to the more centrally located MG binding site (Figures 2E and 4).
The two R6G binding sites are mutually exclusive since, although
the coordinate error of the structure indicates that it may be
possible to refine R6G into the two binding sites simultaneously,
these sites still overlap. Moreover, fluorescence anisotropy binding
measurements confirmed that as per wt QacR, QacR(E90Q) binds
to R6G in a single drug molecule per QacR dimer stoichiometry
(Figure S9). This assertion was further supported by the statistical
disorder of the side chains of QacR residues E90Q and E120, each
of which appear to have a conformation mutually exclusive with
one or the other of the two R6G molecules (Figures 2D–E). In the
wt binding site of the QacR(E90Q)-R6G complex, the orientation
of the amino acid side chains, including those of E90Q and E120,
are identical to those observed in the wt QacR-R6G complex.
Nevertheless, in the absence of the side chain carboxylate of E90,
the charge complementation of R6G appears to be assumed
appreciably by dipole-charge interactions mediated by the side
chain oxygen atoms of Q64 and Q96, located within 3.0 and
3.5 A ˚ of the R6G N2 and N1 ethyl amino nitrogen atoms,
respectively.
The new R6G binding site is created due to the partial occlusion
of the wt site by an alternate conformation adopted by the E90Q
Figure 4. Convergent QacR mutant E90Q and wild type QacR
drug-binding sites. Superimposition of the structures of the
multidrug-binding pockets of wild type QacR-malachite green (MG;
light blue ribbon), QacR(E90Q)-ethidium (Et; pink ribbon), and
QacR(E90Q)-rhodamine 6G (R6G; yellow ribbon) structures. Helices
containing drug-interacting residues are labelled in black.
doi:10.1371/journal.pone.0015974.g004
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the E120 side chain (Figures 2D–E). In this new position, E120
formally complements the R6G N1 nitrogen atom (Table S2).
Notably here, R6G also shifts away from contacts with the side
chains of residues W61, Q64, T89, Y93, and makes a new van der
Waals contact with N157 and new stacking interactions with Y103
and F1629. Strikingly, this binding site is denoted by strong drug
density and, also since the R6G binding affinity and induction
capabilities of QacR(E90Q) are equivalent to those of wt QacR,
this demarks a second physiologically functional and isoenergetic
binding site for R6G. Indeed, the thermal parameters of the R6G
molecule in this site are somewhat lower than those of the R6G
occupying the originally described binding site (Table S1).
However, this site appears to exist only in the context of
substitution of residue E90.
Thus, QacR(E90Q) contains multiple surfaces employing
distinct residue complements capable of isoenergetic Et and
R6G binding and induction. Somewhat similarly, the structures of
wt QacR in complex with ligands DB75 and DB359 revealed that
these bivalent cationic drugs, as ascertained by their weak and
missing electron density, bound in multiple orientations within the
multidrug-binding pocket [32]. This capacity to bind to the same
ligand in multiple orientations also extends to other multidrug-
binding proteins, all of which appear to be characterized
collectively by voluminous pockets that predominantly employ
aromatic stacking interactions for ligand binding. For example, the
human pregnane X receptor (PXR) when crystallized in complex
with SR12813, one of myriad xenobiotics to which PXR binds, is
observed in three distinct binding sites [33]. The Lactococcus lactis
gene regulator LmrR binds daunomycin in two conformations,
both of which utilize stacking with tryptophan residues as an
integral part of binding [34]. A single ligand was observed in
multiple positions in the multi-ligand binding pocket of the pig
odorant binding protein [35]. TtgR binds the plant flavonoid
phloretin in high affinity and low affinity sites simultaneously [19],
and finally, Pgp has been shown recently to bind a novel cyclic
inhibitor (QZ59-SSS) in two locations [36].
Given the subtle impact of the E90Q substitution on the overall
structure and, for the most part, on the orientations of the amino
acid side chains in the QacR multidrug-binding pocket, it is
interesting that these alternate isoenergetic binding sites for Et and
R6G have not been observed previously in the wt QacR-drug
complexes. The alternate drug-binding sites suggest that the
electrostatic contributions of the surrounding acidic residues
extend beyond the immediate proximity of each drug observed
in the wt QacR. Moreover, the influence of the microenvironment
on the formal charge of the glutamates might dictate the preferred
location of each drug in the wt protein as well as the shape and
local plasticity of the binding pocket. Of course other favourable
and unfavourable protein-drug interactions such as p-p and
cation-p interactions and steric factors also influence the location
of the drug-binding site.
Conclusion
The similarity between the drug affinities of the mutant and wt
QacR proteins for all of the drugs tested here points towards the
conclusion that at least for QacR, individual electrostatic
interactions between a drug and a proximal ‘‘neutralizing’’
glutamate in the binding pocket are not major contributors to
binding affinity. Indeed, a similar lack of effect on drug binding
affinity was observed when QacR residues E57 and E58 were
substituted with glutamine or alanine [21] and even when double
glutamate substitutions (E57Q/E58Q) were made (Peters et al.,
data not shown). Thus, other protein-drug interactions, most likely
aromatic side chain-drug stacking, contribute more significantly to
drug-binding affinity. Although formally neutral, aromatic resi-
dues offer the ability to interact electrostatically as well as engage
in van der Waals interactions. Moreover, inspection of the ligand-
binding pockets of both multidrug efflux transport proteins [36–
39] and other multidrug-binding transcription regulators reveals a
plethora of aromatic residues [12,13,20,28]. This is not to suggest
that all multidrug-binding proteins do not utilize acidic residues to
form strong interactions with their ligands. Indeed, AcrR shows
significant effects upon removal of the sole aspartate of the
multidrug-binding pocket [13]. However, BmrR exhibits only
drug-specific binding defects, whereby R6G binding affinity drops
nearly 100-fold in the E253Q substituted protein but Be affinity
does not change [12]. Thus, for QacR the formal negative charges
of the glutamates may be more important as a guiding mechanism
to steer cationic drugs into the binding pocket. Furthermore, their
redundancy in QacR allows the loss of anyone of them with little
impact on function. Perhaps, such redundancy is common for
multidrug-binding proteins that bind both monovalent and
bivalent compounds and those proteins, which bind only
monovalent compounds, may not display such functional re-
dundancy. An additional nonexclusive role for the binding pocket
glutamates of QacR may be to exclude anionic and zwitterionic
drugs that could otherwise bind to QacR through charge-charge
or charge-dipole repulsion.
Thus, binding site selection of cationic drugs in the QacR
multidrug-binding pocket may be driven by a modulated,
electrostatic tug-of-war that is in no small part driven by the
formal negative charge carried by glutamate residues. Further-
more, these key glutamate residues lining the QacR multidrug-
binding pocket may collectively provide a formal negatively
charged pathway geared to drive cationic ligands, as much as their
structures will sterically allow, toward switch residues T89-T93 at
the base of the pocket. This may be a calculated means of ensuring
that cationic compounds are adequately inserted to trigger the
induction of transcriptional regulators or their translocation
mediated by multidrug transporters.
Materials and Methods
Bacterial strains and growth conditions
All cloning and over-expression procedures performed in
Escherichia coli utilized strain DH5a and in Staphylococcus aureus
strain RN4220 norA::erm (SAK1759) [24]. Strains were cultured at
37uC in Luria-Bertani broth or agar containing, where appropri-
ate, 100 mg/ml ampicillin for E. coli or 20 mg/ml erythromycin
and 10 mg/ml chloramphenicol for S. aureus. E. coli was
transformed by standard procedures [40] and S. aureus by
electroporation as described previously [41], employing a pulse
of 1.3 kV.
DNA isolation and manipulations
The Quantum Prep plasmid miniprep kit (Bio-Rad) and small-
scale alkaline lysis procedure [42] were employed to isolate
plasmid DNA from E. coli and S. aureus, respectively. Restriction
enzymes, T4 DNA ligase, calf intestinal alkaline phosphatase, Pfu
DNA polymerase, and Taq DNA polymerase (all from New
England Biolabs), were each used according to the manufacturer’s
instructions. Oligonucleotides were purchased from GeneWorks
(Australia) and Invitrogen Corporation (Carlsbad, California).
PCR products were purified with the Wizard PCR Prep kit
(Promega) and DNA fragments were isolated from agarose gels
using the GFX PCR and Gel Band Purification Kit (Amersham
Biosciences).
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QacR mutants E90A, E90Q, E120A and E120Q were obtained
by generating a PCR-derived fragment encompassing the residue
to be mutated and replacing the wt sequence as previously
described [43]. The K67S substitution, which was found to aid in
crystallization, was added to both of the E90Q and E120Q-
substituted qacR genes using the QuikChange
TM mutagenesis
protocol (Stratagene). The QacR K67S substitution elicited no
observable change in affinity for R6G or IR1 DNA as measured
by fluorescence polarization (data not shown). Similar to the
C72A/C141S QacR derivative [9], the K67S substitution was
thus considered to be a background substitution. Automated DNA
sequencing, performed at the Australian Genome Research
Facility (Brisbane, Australia), was employed to verify the presence
of the desired mutations and the absence of spurious mutations
that may have been introduced during PCR.
Protein preparation
Mutant and wt QacR proteins were over-expressed from E. coli
cells carrying plasmid derivatives of pSK5676, purified by Ni
2+-
NTA metal chelate affinity chromatography (Invitrogen ProBond
resin) as previously described [44], and dialysed against buffer A (1
M NaCl, 20 mM Tris-HCl, 5% [v/v] glycerol, pH 7.5) for
tryptophan fluorescence quenching or buffer B (100 mM NaCl,
15 mM Tris-HCl, 2.5% [v/v] glycerol, pH 7.5) for ITC.
Ligand binding affinity
Tryptophan fluorescence intensity measurements of QacR
proteins were performed and Kd values calculated as described
previously [44]. Each of the reported Kd values represents an
average of three separate Kd determinations. Affinity of QacR
proteins for Dq was measured using a VP-ITC microcalorimeter
(MicroCal) using protocols as described previously [30].
Stoichiometry determination
Stoichiometry of QacR(E90Q)-R6G binding was determined by
fluorescence polarization using a Beacon 2000 (Invitrogen)
fluorescence polarimeter and excitation and emission wavelengths
of 490 nm and 560 nm, respectively. R6G was dissolved in buffer
B to a final concentration of 1.0 mM and QacR(E90Q) was
titrated into the solution up to a final concentration of 5.0 mM.
Protein stability
QacR protein was detected in whole cell lysates of S. aureus
SAK1759 containing the desired plasmid using a rabbit polyclonal
QacR antibody [9] as previously described [43].
b-lactamase reporter gene assays
b-lactamase activities of S. aureus SAK1759 cells containing the
plasmid of interest, were determined using the chromogenic
substrate nitrocefin (Oxoid) as described previously [43,45] and
are presented such that 1 unit corresponds to 1 mM nitrocefin
hydrolyzed/min at 37uC. Results represent the average of two
experiments.
Crystallization, data collection and structure
determination of mutant QacR-drug complexes
Purified QacR mutant proteins were subjected to reductive
alkylation of lysines [3,46], concentrated to 10 mg/ml and buffer
exchanged into 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, and
5% glycerol. The resulting protein preparations were incubated
with 50–500 mM Et, Dq, MG, or R6G. Crystallization was
performed using the hanging drop vapour diffusion method, with
each QacR-drug complex mixed 1:1 with the crystallization
solution of 2.3-2.7 M ammonium sulphate and 50–150 mM
sodium acetate pH 4.6.
X-ray intensity data from the QacR(E120Q)-R6G, Qa-
cR(E120Q)-Dq, QacR(E90Q)-R6G and QacR(E90Q)-Et complex
crystals were collected using ALS beam line (BL) 4.2.2;
QacR(E90Q)-MG, QacR(E90Q)-Et complex crystals at ALS BL
8.2.2 and the QacR(E90Q)-Dq data at ALS BL 8.2.1 at 100K.
Data were processed with MOSFLM and scaled with SCALA
[47,48]. QacR(E90Q) and QacR(E120Q) in complex with R6G
and Dq crystallized in the native P42212 space group whereas
crystals of QacR(E90Q) and QacR(E120Q) in complex with Et
and MG took the hexagonal space group P62. The structures were
solved using MOLREP and the wt QacR structure as a search
model (minus solvent and residue 90 or 120) and refined with
Refmac5, as implemented in CCP4 [47]. The programs O and
Coot were used to visualize and manipulate experimental electron
density maps and structures for model building [49,50]. The
stereochemistry of each structure was validated by MolProbity
[51] and PROCHECK [52]; PROCHECK was also used for
Ramachandran analysis. Table S1 lists selected data collection and
refinement statistics for each of the complexes.
Figures 1-4 were prepared with Chimera [53] and Figures S6–
S8 were generated in Pymol [54]. Structural alignments were
performed in O using the least-squared fitting function (LSQ-
EXP/MOL) [50]. The center-to-center distances of the recogni-
tion helices (a3) were measured by averaging the positions of
the Ca atoms of the residues 37–40 in the middle of each
recognition helix and the distance between each of these
helical centers determined by the Pythagorean distance
formula. Conformational changes were measured with DymDom
[55].
Supporting Information
Figure S1 Stoichiometry of dequalinium binding to wild type
QacR. Representative thermogram and data plot is shown.
Statistics were compiled from three individual experiments. The
binding stoichiometry of greater than one plus the large error
reflects errors in the concentrations of protein and drug and their
insolubility at higher concentrations.
(TIF)
Figure S2 Stoichiometry of dequalinium binding to the
QacR(E90A) mutant. Representative thermogram and data plot
showing dequalinium binding to QacR(E90A). Statistics were
compiled from five individual experiments. The binding stoichi-
ometry of greater than one plus the large error reflects errors in the
concentrations of protein and drug and their insolubility at higher
concentrations.
(TIF)
Figure S3 Stoichiometry of dequalinium binding to the
QacR(E90Q) mutant. Representative thermogram and data plot
is shown. Statistics were compiled from four individual experi-
ments. The binding stoichiometry of greater than one plus the
large error reflects errors in the concentrations of protein and drug
and their insolubility at higher concentrations.
(TIF)
Figure S4 Stoichiometry of dequalinium binding to the
QacR(E120A) mutant. Representative thermogram and data plot
is shown. Statistics were compiled from four individual experi-
ments. The binding stoichiometry of greater than one plus the
QacR Binding Site Selection
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and their insolubility at higher concentrations.
(TIF)
Figure S5 Stoichiometry of dequalinium binding to the
QacR(E120Q) mutant. Representative thermogram and data plot
is shown. Statistics were compiled from three individual
experiments. The binding stoichiometry of greater than one plus
the large error reflects errors in the concentrations of protein and
drug and their insolubility at higher concentrations.
(TIF)
Figure S6 2Fo-Fc composite omit electron density maps of
QacR(E90Q). In complex with (A) dequalinium, (B) ethidium, (C)
malachite green and (D) rhodamine 6G. Molecules are shown as
sticks with carbon, nitrogen and oxygen atoms coloured yellow,
blue and red, respectively. Two molecules of imidazole are shown
in panel C and labelled IMD1 and IMD2. The contour level is
1.0 s.
(TIF)
Figure S7 2Fo-Fc composite omit electron density maps of
QacR(E120Q). In complex with (A) dequalinium, (B) malachite
green and (C) rhodamine 6G. Molecules are shown as sticks with
carbon, nitrogen and oxygen atoms coloured orange, blue and
red, respectively. Two molecules of imidazole are shown in panel
B and labelled IMD1 and IMD2. The contour level is 1.0 s.
(TIF)
Figure S8 Superimposition of the helix-turn-helix motifs of
QacR(E90Q)-malachite green and DNA-bound wild type QacR.
Overlay of the QacR(E90Q)-malachite green (yellow) and DNA-
bound wild type QacR (orange) helix-turn-helix motifs reveals
multiple steric clashes between the QacR(E90Q) and the IR1
binding site. Molecules are shown as sticks with nitrogen and
oxygen atoms coloured blue and red, respectively. Notably, the b
carbon of residue Thr24 (helix a2) is 0.7 A ˚ from the phosphate
backbone of thymidine (dT) E24 O39 and the b carbon of K36 at
the N-terminus of the recognition helix is 2.1 A ˚ from the O4 of
thymidine (dT) E27 and 2.7 A ˚ from the C7 methyl group.
(TIF)
Figure S9 Stoichiometry of rhodamine 6G binding to the
QacR(E190Q) mutant. Representative determination of binding
stoichiometry utilizing fluorescence polarization is shown. The
value is one drug molecule bound per QacR dimer. All drugs
examined with intrinsic fluorescence give the same stoichiometry.
(TIF)
Table S1 Selected data collection and refinement statistics of the
eight crystal structures.
(DOC)
Table S2 Distances between residues E57, E58, E90 and E120,
and dequalinium, ethidium, malachite green, and rhodamine 6G
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